Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

ABSTRACT: This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: * Find the recommended dose of IMT-009 that can be safely given to participants * Learn more about the side effects of IMT-009 * Learn more about pharmacokinetics of IMT-009 * Learn more about the effectiveness of IMT-009 * Learn more about different pharmacokinetic biomarkers and how they might change in the presence of IMT-009

DISEASE(S): Lymphoma, Large B-cell, Diffuse,Carcinoma,Triple Negative Breast Neoplasms,Hodgkin Disease,Colorectal Cancer,Non Small Cell Lung Cancer,Triple Negative Breast Cancer,Hormone Receptor Positive Breast Carcinoma,Breast Neoplasms,Cutaneous Squamous Cell Carcinoma,Small Bowel Cancer,Hodgkin Lymphoma,Esophageal Neoplasms,Colorectal Neoplasms,Carcinoma, Non-small-cell Lung,Head And Neck Squamous Cell Carcinoma,Lymphoma, T-cell,Lymphoma, T-cell, Peripheral,Solid Tumor,Diffuse Large B Cell Lymphoma,Burkitt Lymphoma,Diffuse Large B-cell Lymphoma,Lymphoma,Carcinoma, Squamous Cell,Squamous Cell Carcinoma Of Head And Neck,T-cell Lymphoma,Esophageal Cancer,Lymphoma, B-cell

PROVIDER: 2750284 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Project description:This clinical trial is evaluating a drug called SNX281 given by itself and in combination with pembrolizumab in participants with advanced solid tumors and lymphoma. The main goals of this study are to: * Find the recommended dose of SNX281 that can be given to participants safely alone and in combination with pembrolizumab. * Learn more about the side effects and safety profile of SNX281 alone and in combination with pembrolizumab * Learn more about pharmacological characteristics of SNX281 alone and in combination with pembrolizumab * Learn more about effectiveness of SNX281 alone and in combination with pembrolizumab

| 2356224 | ecrin-mdr-crc

A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.

Project description:This is a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that have select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal growth factor receptor (EGFR/ErbB1). The main goals of this study are to: * Find the recommended dose of BDTX-189 that can be given safely to participants * Learn more about the side effects of BDTX-189 * Learn what the body does to BDTX-189 after it has been taken (pharmacokinetics or PK) * Determine the antitumor activity of BDTX-189 in participants with select allosteric ErbB gene mutations

| 2325490 | ecrin-mdr-crc

B cell Lymphomas present Immunoglobulin Neoantigens

Project description:Immunoglobulin gene rearrangement and somatic hypermutation have the potential to create neoantigens in non-Hodgkin B cell lymphoma. However, the presentation of these putative immunoglobulin neoantigens by B cell lymphomas has not been proven. We used MHC immunoprecipitation followed by liquid chromatography and tandem mass spectrometry (LC-MS/MS) to define antigens presented by follicular lymphomas (FL), chronic lymphocytic leukemias (CLL), diffuse large B cell lymphoma (DLBCL) and mantle cell lymphomas (MCL). We found presentation of the clonal immunoglobulin molecule, including neoantigens by both class I and class II MHC, though more commonly in class II MHC. To determine whether B cell activation could promote presentation of immunoglobulin neoantigens, we used a toll-like receptor 9 (TLR9) agonists to upregulate expression of MHC-II. This resulted in enhanced class II MHC presentation of the immunoglobulin variable region including neoantigens. These findings demonstrate that immunoglobulin neoantigens are presented across most subtypes of B cell lymphomas. Activation of lymphoma cells to upregulate antigen presentation boosts presentation of immunoglobulin neoantigens and represents a strategy for augmenting lymphoma immunotherapies.

2019-01-07 | PXD010808 | Pride

Serum DIA LC-MS of ocular adnexal lymphomas and controls

Project description:Ocular adnexal lymphoma is a rare subtype of non-Hodgkin lymphoma. DIA LC-MS of serum samples collected at diagnosis was performed on 38 ocular adnexal lymphomas (28 extranodal marginal zone lymphomas, and 10 diffuse large B-cell lymphomas), and 20 controls (10 idiopathic orbital inflammation, and 10 reactive lymphoid hyperplasia). Complete clinicopathologic features of these patients were collected.

2022-10-18 | PXD037536 |

Gamma-irradiation induced T-cell lymphomas (miRNA study)

Project description:This set of data contains the expression levels of cDNAs in T-cell lymphoblastic lymphomas induced by gamma-irradiation. These tumor samples were compared to normal thymuses Keywords: Tumor profiles, comparison of tumoral versus wild-type tissues, lymphomas and leukemias C57BL/6J animals were maintained in our animal facilities following the appropriate ethical recommendations from our institutions. For tumor induction, 4-week-old mice of both sexes were exposed to four weekly doses of 1.75 Gy/dose of ionizing gamma radiation. Treated mice were observed daily until moribund, then sacrificed and autopsied. DNA, RNA and proteins were isolated from these samples using routine procedures.

2010-05-26 | E-GEOD-10891 | biostudies-arrayexpress

Comparative Genomic hybridization of gamma-irradiated T-cell lymphomas

Project description:This analysis compares the signal of DNA from T-cell lymphoblastic lymphomas induced by gamma-irradiation versus normal thymuses Keywords: Tumor profiles, comparison of tumoral versus wilf-type tissues, lymphomas and leukemias C57BL/6J animals were maintained in our animal facilities following the appropriate ethical recommendations from our institutions. For tumor induction, 4-week-old mice of both sexes were exposed to four weekly doses of 1.75 Gy/dose of ionizing gamma radiation. Treated mice were observed daily until moribund, then sacrificed and autopsied. DNA, RNA and proteins were isolated from these samples using routine procedures.

2010-05-26 | E-GEOD-10858 | biostudies-arrayexpress

Biologic characterization of adult MYC-positive mature B-cell lymphomas other than molecular Burkitt lymphoma

Project description:MYC translocations are the biologic hallmark of Burkitt lymphomas but also occur in other mature B-cell lymphomas. If accompanied by chromosomal breaks targeting the BCL2 and/or BCL6 oncogenes, these MYC translocation-positive (MYC+) lymphomas are called double-hit lymphomas (DHLs); otherwise, the term single-hit lymphoma (SHL) is applied. In order to characterize the biologic features of these MYC+ lymphomas other than Burkitt lymphomas, we explored, after exclusion of molecular Burkitt lymphoma (mBL) as defined by gene expression profiling (GEP), the molecular, pathological and clinical aspects of 80 MYC translocation (MYC+) lymphomas (31 SHL, 26 BCL2+/MYC+, 14 BCL6+/MYC+, 6 BCL2+/BCL6+/MYC+ and 3 MYC+ lymphomas with unknown BCL6 status). Comparison of SHL and DHL revealed no difference in frequency of MYC partner (IG/non-IG), genomic complexity or MYC expression and no differences in GEP. DHL showed a more frequent GCB-like GEP and higher IGH and MYC mutation rates. GEP revealed 130 differentially expressed genes between BCL6+/MYC+ and BCL2+/MYC+ DHL. BCL2+/MYC+ DHL showed a more frequent GCB-like GEP. Analysis of all lymphomas according to MYC partner (IG/non-IG) revealed no substantial differences. In contrast to mBL and lymphomas without MYC break, SHL and DHL patients had similar poor outcome. Our data suggest that after excluding mBL, MYC+ lymphomas could be biologically widely lumped without further need for subclassification.

2013-12-31 | GSE44164 | GEO

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

Project description:RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of carboxyamidotriazole and paclitaxel in treating patients with advanced solid tumors or refractory lymphomas.

| 2006371 | ecrin-mdr-crc

Expression patterns of cDNAs in gamma-irradiation induced T-cell lymphomas

Project description:This set of data contains the expression levels of cDNAs in T-cell lymphoblastci lymphomas induced by gamma-irradiation. These tumor samples were compared to normal thymuses Keywords: Tumor profiles, comparison of tumoral versus wilf-type tissues, lymphomas and leukemias C57BL/6J animals were maintained in our animal facilities following the appropriate ethical recommendations from our institutions. For tumor induction, 4-week-old mice of both sexes were exposed to four weekly doses of 1.75 Gy/dose of ionizing gamma radiation. Treated mice were observed daily until moribund, then sacrificed and autopsied. DNA, RNA and proteins were isolated from these samples using routine procedures.

2010-05-26 | E-GEOD-10859 | biostudies-arrayexpress

The effect on gene expression of Smchd1 deletion in end stage lymphomas

Project description:Smchd1 appears to act as a tumour suppressor in the Eµ-Myc B cell lymphoma model. We find gene expression differences are most pronounced in the premalignant cells, and observe more variability in end stage lymphomas. We always detect a small number of clustered genes and imprinted genes as differentially expressed, along with others involved in tumorigenesis. The microarrays compared Smchd1 null and Smchd1 wildtype samples from end stage lymphomas. All lymphomas are on the C57BL/6 background and carry the Eµ-Myc transgene, and Smchd1 null samples are additionally homozygous for a Smchd1 genetrap allele.

2012-09-30 | E-GEOD-40880 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data